Gentian Diagnostics ASA

Earnings Release • Jul 31, 2024

Gentian Diagnostics presents its NT-proBNP prototype at the ADLM

Gentian Diagnostics presents its NT-proBNP prototype at the ADLM

Chicago, 31 July 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, is pleased to announce that the results related to the development of its turbidimetric NT-proBNP assay were presented at the Association for Diagnostics & Laboratory Medicine (ADLM) 2024 clinical meeting, in Chicago, with a poster titled: Development and diagnostic utility of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP.

The presented results demonstrate good analytical performance of the Gentian assay prototype and confirm the impact of glycosylation on measurement of NT-proBNP in patient samples.

Current commercial assays mostly use antibodies that bind to the central region of NT-proBNP, which is typically glycosylated. The glycosylation significantly affects quantification of NT-proBNP in patient samples, as up to 80% of NT-proBNP may be glycosylated in this region. The glycosylation restricts antibody binding and thereby protein detection, leading to underestimation of NT-proBNP levels.

Our results demonstrate the underestimation of NT-proBNP levels by assays based on antibodies targeting glycosylated regions of NT-proBNP. In contrast, Gentian's NT-proBNP prototype assay targets glycosylation-free regions of the protein and detects endogenous NT-proBNP regardless of its glycosylation status. Our results confirm that inaccuracies caused by glycosylation are avoided by analysis of NT-proBNP with Gentian NT-proBNP assay.

An instrument variation study showed strong correlation between values measured on instruments from different manufacturers. These results confirm the value of the Gentian prototype as easily accessible and available on different instrument platforms, improving availability of the assay as well as cost and workflow efficiency.

Please find the poster attached to this press release.

About Gentian Diagnostics

Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

IR contact:

Njaal Kind, CEO

njaal.kind@gentian.no

+47 919 06 525 (mobile)